Thursday 16 October, 2025
Introduction: The optimal drug and dosage for treating acute delirium lack consensus, especially among critically ill patients whose altered pharmacokinetics…
Read morePoster: Drug/Disease Modelling - CNS
An Exploratory Analysis of the Performance of Methylphenidate Regimens Based on a PKPD Model of Dopamine and Norepinephrine Transporter Occupancy
Thursday 16 October, 2025
Introduction: Methylphenidate (MPH) is a psychostimulant which inhibits the uptake of dopamine and norepinephrine transporters, DAT and NET, and is…
Read moreDonepezil brain and blood pharmacokinetic modeling after nasal film and oral solution administration in mice
Thursday 16 October, 2025
Introduction: The pharmacokinetic (PK) model development for nasal delivery is a challenging process without adequate literature reports. Intravenous PK models…
Read moreOptimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer model
Thursday 16 October, 2025
Introduction/Objectives: N,N-dimethyltryptamine (DMT) is a psychedelic compound that is currently being studied as a treatment option in a number of…
Read morePredicting individual disease progression including parameter uncertainty in rare neurodegenerative diseases: the example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS)
Thursday 16 October, 2025
Objectives: Genetic cerebellar ataxias are ultra-rare progressive neurological diseases (RNDs) affecting the cerebellum, often with multisystemic damage to other neurological…
Read moreApplication of interspecies PBPK modeling to characterize BBB permeability and assess target site exposure-response using levetiracetam as model drug
Thursday 16 October, 2025
Introduction: Adequate delivery of drugs at the central nervous system (CNS) level is a prerequisite for drugs in epilepsy. However,…
Read moreA mechanistic model of pure and lipid-mediated alpha-synuclein aggregation to advance therapeutic strategies against Parkinson’s disease
Thursday 16 October, 2025
Objectives: The neuronal protein alpha-synuclein (aSyn) holds a crucial role in the intricate molecular landscape of Parkinson’s disease. While aSyn…
Read moreA mechanistic model of α-synuclein aggregation and degradation to bridge in vitro and in vivo research on Parkinson’s disease.
Thursday 16 October, 2025
Objectives: Parkinson’s disease is a debilitating neurodegenerative disorder characterized by an intricate network of molecular mechanisms [1]. Such a biological…
Read morePopulation pharmacokinetics of aripiprazole and its active metabolite dehydroaripiprazole in subjects receiving once-monthly intramuscular aripiprazole.
Thursday 16 October, 2025
Introduction: Aripiprazole is an antipsychotic whose systemic metabolism is mainly carried out by hepatic biotransformation, mediated by CYP2D6 and, to…
Read moreSimulation of Rituximab and Natalizumab biomarker efficacy using simplified QSP model of B- and T- lymphocyte dynamics in Multiple Sclerosis
Thursday 16 October, 2025
Introduction: Immune-mediated disease affecting the CNS, multiple sclerosis (MS), is the leading cause of neurological disability among people aged from…
Read more